Mostrar el registro sencillo del ítem
dc.contributor.author
Enrico, Alicia
dc.contributor.author
Bestach, Yesica Soledad
dc.contributor.author
Flores, Maria Gabriela
dc.contributor.author
Arbelbide, Jorge
dc.contributor.author
Serale, Camila
dc.contributor.author
Novoa, Viviana
dc.contributor.author
Crisp, Renée
dc.contributor.author
Rivas, María Marta
dc.contributor.author
Larripa, Irene Beatriz
dc.contributor.author
Belli, Carolina Bárbara
dc.date.available
2018-11-27T13:53:36Z
dc.date.issued
2017-11
dc.identifier.citation
Enrico, Alicia; Bestach, Yesica Soledad; Flores, Maria Gabriela; Arbelbide, Jorge; Serale, Camila; et al.; Influence of Acute Myeloid Leukemia Progression on the Prognosis of 831 Patients With Myelodysplastic Syndromes From the Argentine Database; Elsevier Inc; Clinical Lymphoma, Myeloma and Leukemia; 17; 11; 11-2017; 743-752.e5
dc.identifier.issn
2152-2650
dc.identifier.uri
http://hdl.handle.net/11336/65275
dc.description.abstract
In our retrospective review of 831 patients with myelodysplastic syndromes, 158 developed progression with a very poor outcome (median survival after evolution, 3.5 months). The survival of patients with adverse karyotypes or with greater International Prognostic Scoring System-revised or World Health Organization-based Prognostic Scoring System risk was not affected when stratified by patients with and without evolution to acute myeloid leukemia. Our results could help in individualizing those patients who require more aggressive treatment. Background A large group of patients with myelodysplastic syndromes (MDS) will die of causes intrinsic to bone marrow failure. One third of patients will develop acute myeloid leukemia (AML), which is associated with an extremely poor outcome and a short survival. Our objectives were to analyze the prognostic variables and scoring systems in the attempt to determine the influence of progression on the overall survival of MDS patients. Patients and Methods We performed a retrospective analysis of 831 MDS patients, including those from the Argentine Registry. Results Of the 831 MDS patients, 158 (19.0%) experienced transformation, with a median overall survival of 17.9 months from diagnosis and 3.5 months after progression. The survival of patients with adverse karyotypes or greater risk, according to the International Prognostic Scoring System-revised (IPSS-R) or World Health Organization-based Prognostic Scoring System (WPSS) was not affected when stratified by patients with and without evolution to AML (P >.05). In contrast, the survival of lower risk patients was significantly reduced for those patients with progression to AML (P <.001) and those younger (P =.024) than those who died of non–AML-related causes. The intermediate-risk patients were heterogeneously distributed; however, an upgrade from a lower IPSS-R to a higher WPSS-hemoglobin risk category was associated with a worse outcome, not affected by progression (P =.420), with a median event-free survival of 16 months. Conclusion The use of the IPSS-R and WPSS systems simultaneously might help in identifying those patients who require more aggressive treatment. Nevertheless, more efforts are needed to improve the identification of those lower risk patients whose survival is significantly reduced by progression to AML.
dc.format
application/pdf
dc.language.iso
eng
dc.publisher
Elsevier Inc
dc.rights
info:eu-repo/semantics/openAccess
dc.rights.uri
https://creativecommons.org/licenses/by-nc-nd/2.5/ar/
dc.subject
International Prognostic Scoring System
dc.subject
Mds
dc.subject
Scoring Systems
dc.subject
Secondary Aml
dc.subject
Wpss
dc.subject.classification
Medicina Critica y de Emergencia
dc.subject.classification
Medicina Clínica
dc.subject.classification
CIENCIAS MÉDICAS Y DE LA SALUD
dc.title
Influence of Acute Myeloid Leukemia Progression on the Prognosis of 831 Patients With Myelodysplastic Syndromes From the Argentine Database
dc.type
info:eu-repo/semantics/article
dc.type
info:ar-repo/semantics/artículo
dc.type
info:eu-repo/semantics/publishedVersion
dc.date.updated
2018-10-23T20:21:03Z
dc.journal.volume
17
dc.journal.number
11
dc.journal.pagination
743-752.e5
dc.journal.pais
Estados Unidos
dc.description.fil
Fil: Enrico, Alicia. Hospital Italiano de la Plata. Area Hematologia; Argentina
dc.description.fil
Fil: Bestach, Yesica Soledad. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Medicina Experimental. Academia Nacional de Medicina de Buenos Aires. Instituto de Medicina Experimental; Argentina
dc.description.fil
Fil: Flores, Maria Gabriela. Gobierno de la Ciudad de Buenos Aires. Hospital General de Agudos C. Durand; Argentina
dc.description.fil
Fil: Arbelbide, Jorge. Hospital Italiano; Argentina
dc.description.fil
Fil: Serale, Camila. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Medicina Experimental. Academia Nacional de Medicina de Buenos Aires. Instituto de Medicina Experimental; Argentina
dc.description.fil
Fil: Novoa, Viviana. Gobierno de la Ciudad de Buenos Aires. Hospital General de Agudos C. Durand; Argentina
dc.description.fil
Fil: Crisp, Renée. Hospital Nacional Profesor Alejandro Posadas; Argentina
dc.description.fil
Fil: Rivas, María Marta. Hospital Universitario Austral; Argentina
dc.description.fil
Fil: Larripa, Irene Beatriz. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Medicina Experimental. Academia Nacional de Medicina de Buenos Aires. Instituto de Medicina Experimental; Argentina
dc.description.fil
Fil: Belli, Carolina Bárbara. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Medicina Experimental. Academia Nacional de Medicina de Buenos Aires. Instituto de Medicina Experimental; Argentina
dc.journal.title
Clinical Lymphoma, Myeloma and Leukemia
dc.relation.alternativeid
info:eu-repo/semantics/altIdentifier/doi/http://dx.doi.org/10.1016/j.clml.2017.06.024
dc.relation.alternativeid
info:eu-repo/semantics/altIdentifier/url/https://www.sciencedirect.com/science/article/pii/S2152265016309387
Archivos asociados